Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - Kelley, R K; Rimassa, L; Cheng, A L (Lancet Oncol, 2022)